SCHEMBL5030320

SCHEMBL5030320

CC(C)(C)N[C@@H]1CC[C@H](NC(=O)CNC(=O)c2ccc(-c3ccc(Cl)cc3)o2)[C@@H](CO)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 5/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 4/20 0.41
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
MMP13 P45452 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5030317 1.00 NPC1 (0.48) NPC1RAB9AL3MBTL1MAPK11MAPK14
SCHEMBL5027311 0.90 NPC1 (0.46) NPC1RAB9AL3MBTL1MAPK11MAPK14
SCHEMBL5027309 0.90 NPC1 (0.46) NPC1RAB9AL3MBTL1MAPK11MAPK14
SCHEMBL5027304 0.90 NPC1 (0.46) NPC1RAB9AL3MBTL1MAPK11MAPK14
SCHEMBL5033745 0.74 LMNA (0.39) NPC1RAB9AL3MBTL1ALDH1A1PKM
SCHEMBL5033751 0.74 LMNA (0.39) NPC1RAB9AL3MBTL1ALDH1A1PKM
SCHEMBL5030336 0.73 CCR2 (0.53)
SCHEMBL5030345 0.73 CCR2 (0.53)
SCHEMBL5030311 0.72 CCR2 (0.41) RAB9A
SCHEMBL5030282 0.72 CCR2 (0.41) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 NPC1 1002/4885RAB9A 2580/4885L3MBTL1 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.